Syncom Formulations (India) Ltd.
Snapshot View

8.12 +0.13 ▲1.6%

27 June 2022, 04:01:00 PM
Volume: 894,207

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sfil.in
Market Cap 763.28 Cr.
Enterprise Value(EV) 820.69 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 0.21 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 38.57 Trailing Twelve Months Ending 2022-03
Industry PE 29.84 Trailing Twelve Months Ending 2022-03
Book Value / Share 2.57 Trailing Twelve Months Ending 2022-03
Price to Book Value 3.16 Calculated using Price: 8.12
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 94.00 Cr. 940,000,000 Shares
FaceValue 1
Company Profile
Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.63%
1 Week
+27.27%
1 Month
-5.58%
3 Month
-29.58%
6 Month
-13.89%
1 Year
+2.27%
2 Year
+262.50%
5 Year
+437.75%
10 Year
+407.50%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 6.60 10.19 9.99 9.91 9.56 7.33 8.71 10.24 18.04
Return on Capital Employed (%) 9.98 15.29 15.55 14.72 13.58 9.43 9.37 12.39 20.68
Return on Assets (%) 4.76 6.95 6.82 6.41 5.93 4.90 6.34 7.92 12.02

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 88 95 100 109 114 122 133 146 188 222
Non Curr. Liab. 8 7 6 6 8 9 8 7 7 8
Curr. Liab. 29 42 37 66 56 43 36 31 106 78
Minority Int.
Equity & Liab. 124 144 143 181 179 174 176 184 301 308
Non Curr. Assets 63 66 59 89 92 93 95 95 102 168
Curr. Assets 62 78 83 92 87 81 81 89 200 140
Misc. Exp. not W/O
Total Assets 124 144 143 181 179 174 176 184 301 308

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 115 151 173 184 185 159 187 206 245 220
Other Income 1 1 2 3 3 4 5 5 7 12
Total Income 116 152 175 187 188 163 192 211 252 232
Total Expenditure -104 -135 -155 -167 -168 -147 -175 -189 -207 -200
PBIDT 12 17 20 19 19 16 17 22 45 31
Interest -1 0 0 0 0 0 0 -1 0 -1
Depreciation -3 -3 -3 -3 -3 -4 -4 -4 -4 -4
Taxation -3 -5 -6 -6 -5 -3 -2 -3 -12 -6
Exceptional Items -1 0 0 0 0 0 0
PAT 6 9 10 10 11 9 11 14 29 20
Adjusted EPS 0 0 0 0 0 0 0 0 0 0

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 6 6 7 0 24 17 -2 4 6 -2
Cash Fr. Inv. -5 0 -4 1 -23 -8 -2 2 2 -73
Cash Fr. Finan. -1 -6 -1 1 -2 -2 -2 0 -7 72
Net Change 1 -1 2 2 -1 6 -6 7 1 -3
Cash & Cash Eqvt 5 4 5 7 6 7 1 7 8 5

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 40.14 40.48 40.48 40.48 41.18 41.18 44.01 44.01 46.12
Public 59.86 59.52 59.52 59.52 58.82 58.82 55.99 55.99 53.88
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 09 Jun 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Shri Kedarmal Shankarlal Bankda & PACs
Thu, 09 Jun 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Shri Kedarmal Shankarlal Bankda & PACs
Thu, 09 Jun 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Vijay Shankarlal Bankda & PACs

Technical Scans View Details

Mon, 27 Jun 2022
Closing Above Previous High Closing Above Previous High
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Increase 2 Years High Increase 2 Years
High Increase 5 Years High Increase 5 Years

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 200,572.41 835.95 +1.4%
Divi's Laboratories Ltd. 97,518.56 3,679.05 0.0%
Cipla Ltd. 75,086.75 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. 71,855.08 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. 54,559.09 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. 48,438.53 2,858.25 -0.6%
Gland Pharma Ltd. 43,775.42 2,658.60 +0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 61.29 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2022-03 32.99 3,679.05 0.0%
Cipla Ltd. Consolidated 2022-03 29.83 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.92 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 51.70 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 62.24 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2022-03 36.13 2,658.60 +0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 4.18 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2022-03 8.33 3,679.05 0.0%
Cipla Ltd. Consolidated 2022-03 3.60 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.68 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.12 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2022-03 6.12 2,658.60 +0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 0.10 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,658.60 +0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 14.13 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,658.60 +0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 14.13 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,658.60 +0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,658.60 +0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,658.60 +0.6%

FAQ's On Syncom Formulations (India) Ltd.

Can I Buy Syncom Formulations Shares now?

What is the Share Price of Syncom Formulations?

What is the Relative Strength Index (RSI) Value of Syncom Formulations?

What is the Market Capital (MCAP) of Syncom Formulations?

What are the key metrics to analyse Syncom Formulations?

What is the Price Performance of Syncom Formulations?